Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients.
Ben-Ari
Z
Z
Liver Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. gbenari@bezeqint.net
Mor
E
E
Bar-Nathan
N
N
Shaharabani
E
E
Shapira
Z
Z
Tur-Kaspa
R
R
D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood / Q000302:isolation & purification; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D016756:Immunoglobulins, Intravenous; D019259:Lamivudine